National MTM Advisory Board Sees Hybrid of P4P and MTM as Best Strategy

Article

PRESS RELEASE

Des Moines, Iowa (September 8, 2014) - The National MTM Advisory Board has released its response to “Medicare star ratings: Stakeholder proceedings on community pharmacy and managed care partnerships in quality,” from the May/June 2014 issue of Journal of the American Pharmacists Association.

The Board, comprised of payor, provider and consumer representatives from the Medication Therapy Management (MTM) industry, agreed with several points made in the article:

  • Collaboration between payors and providers is key.
  • Common goals should focus on outcomes, including patient behavior change.
  • Return on investment should be clear to all parties involved.

The National MTM Advisory Board believes Pay-for-Performance (P4P) and Medication Therapy Management (MTM) programs are not mutually exclusive but rather exist on a continuum. P4P approaches spotlight patient behavior change and meaningful results. MTM provides a framework for achieving desired results, giving providers the resources and best practices necessary to systematically improve performance. The Board sees a hybrid strategy that features elements of both P4P and MTM as superior to approaches from either end of the continuum.

View the full National MTM Advisory Board Position Paper on community pharmacy and managed care partnerships in quality.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.